Long noncoding RNAs (lncRNAs) have been widely proven to be involved in liver lipid homeostasis. Herein, we identify an upregulated lncRNA named lncRP11-675F6.3 in response to rapamycin treatment using a microarray in HepG2 cells. Knockdown of lncRP11-675F6.3 leads to a significant reduction in apolipoprotein 100 (ApoB100), microsomal triglyceride transfer protein (MTTP), ApoE and ApoC3 with increased cellular triglyceride level and autophagy. Furthermore, we find that ApoB100 is obviously colocalized with GFP-LC3 in autophagosomes when lncRP11-675F6. 3 is knocked down, indicating that elevated triglyceride accumulation likely related to autophagy induces the degradation of ApoB100 and impairs very low-density lipoprotein (VLDL) assembly. We then identify and validate that hexokinase 1 (HK1) acts as the binding protein of lncRP11-675F6.3 and mediates triglyceride regulation and cell autophagy. More importantly, we find that lncRP11-675F6.3 and HK1 attenuate high fat diet induced nonalcoholic fatty liver disease (NAFLD) by regulating VLDL-related proteins and autophagy. In conclusion, this study reveals that lncRP11-675F6.3 is potentially involved in the downstream of mTOR signaling pathway and the regulatory network of hepatic triglyceride metabolism in cooperation with its interacting protein HK1, which may provide a new target for fatty liver disorder treatment.
6 October 2022 in Biochemical and Biophysical Research Communications
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is intricately linked to gut–liver axis dysfunction, wherein microbial dysbiosis, bile acid dysregulation, and impaired intestinal barrier function synergistically drive disease pathogenesis. Here, we developed a nanotherapeutic platform using Lactobacillus rhamnosus GG‐derived extracellular vesicles (LGG‐EVs). Cold‐shock fermentation (28°C) doubled the EV yield without compromising bioactivity. Following intraperitoneal administration in high‐fat diet (HFD)‐induced MASLD mice, LGG‐EVs preferentially accumulated in the liver, where they reestablished bile acid homeostasis through Pparα ‐mediated reprogramming of Cyp7a1 and Cyp7b1 expression, reduced hepatic steatosis by suppressing lipogenic gene programs, and attenuated inflammation via inhibition of NF‐κB/MAPK signalling. This hepatic bile acid modulation subsequently alleviated intestinal bile acid accumulation, restored intestinal barrier integrity via upregulation of tight‐junction proteins, and reduced intestinal permeability. These intestinal improvements were accompanied by restoration of gut microbiota composition, marked by enrichment of beneficial taxa such as Akkermansia , Muribaculaceae , and Lachnospiraceae_NK4A136 , alongside reduction in the Firmicutes / Bacteroidota ratio. Collectively, by orchestrating bidirectional liver–gut axis repair–initiated by hepatic bile acid metabolic reprogramming and propagated through gut microbiota restoration and intestinal barrier reinforcement–cold‐shock‐enhanced LGG‐EVs represent a safe, high‐yield nanomedicine for MASLD therapy.